Investors are optimistic about Veracyte (VCYT) led by strength in the testing business and upbeat guidance.
SOUTH SAN FRANCISCO, Calif., May 15, 2024--Veracyte, Inc. (Nasdaq: VCYT) a leading cancer diagnostics company, today announced it will participate in the following investor conferences.
The mean of analysts' price targets for Veracyte (VCYT) points to a 39.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.